Serum tumor marker CA 125 for monitoring ovarian cancer during follow-up

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 62, Issue 3, 2002, Pages 177-188

  Tuxen, M K ^a   Soletormos G ^a   Dombernowsky, P ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Analytical variation; Biological variation; CA 125; Follow up; Monitoring; Ovarian cancer; Progression criteria

Indexed keywords

CA 125 ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PATIENT MONITORING; PRIORITY JOURNAL; BLOOD; DISEASE COURSE; OVARY TUMOR; PREDICTION AND FORECASTING; PROSPECTIVE STUDY;

CA-125 ANTIGEN; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMAN; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; HUMANS;

EID: 0035991109     PISSN: 00365513     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655102317475434     Document Type: Article

References (19)

1. Reactivity of a monoclonal antibody with human ovarian carcinoma
2. Tumor marker CA 125 in ovarian cancer
3. A novel method for monitoring high-risk breast cancer with tumor markers: CA 15.3 compared to CEA and TPA
4. Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow-up
5. Kinetics of serum tumour marker concentrations and usefulness in clinical monitoring
6. Serum tumor marker CA 125 in monitoring of ovarian cancer during first-line chemotherapy
7. Heterophilic antibodies: A problem for all immunoassays
8. Immunoglobulin inhibiting Reagent®: Evaluation of a new method for eliminating spurious elevations in CA 125 caused by HAMA
9. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer
10. Cobas® core CA 125 I1 EIA
11. Biological variation and analytical imprecision of CA 125 in patients with ovarian cancer
12. The importance of imprecision
13. Setting analytical goals for random analytical error in specific clinical monitoring situations
14. Defining progression of ovarian carcinoma during follow-up according to CA 125: A North Thames Ovary Group study
15. Reporting results of cancer treatment
16. Toxicity and response criteria of the Eastern Cooperative Oncology Group
17. Use of CA 125 in follow-up of ovarian cancer
18. Advanced epithelial ovarian cancer: 1998 Consensus statements